Overview
- The Centers for Medicare & Medicaid Services finalized the rule on Tuesday, Aug. 11, 2026, and it will take effect on Oct. 13, 2026.
- The regulation bars federal Medicaid and CHIP payment for puberty blockers, cross‑sex hormones and surgical gender‑affirming procedures for minors while preserving coverage for mental health services.
- Children already receiving hormone therapy may continue to get federally funded medication for up to six months after the rule takes effect so clinicians can phase care, but the taper does not extend to puberty blockers or surgeries.
- The rule does not outlaw procedures; states may continue coverage with their own funds and private insurers are unaffected, which will shift costs and access burdens onto states, families and employers.
- Medical groups and LGBTQ+ advocates say the administration misrepresents clinical evidence and predict lawsuits and state‑federal clashes, while CMS projects about $235 million in combined Medicaid/CHIP savings over the next decade.